Roche has introduced its Axelios 1 platform, a next-generation sequencing system that is available for research use and powered by its sequencing by expansion (SBX) technology.
The system delivers whole-genome sequencing results within hours in research workflows, aiming to address bottlenecks in genomics research through a combination of speed, accuracy, scalability and cost efficiency.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is intended for laboratories of varying sizes, giving researchers the ability to modify workflows and explore diverse applications.
The launch was supported by collaborations with institutions such as the Hartwig Medical Foundation and Broad Clinical Labs.
It also included partnerships for library preparation and analysis tools, including compatibility with 10x Genomics application kits and support for SBX via Google DeepVariant and Roche’s open-source XOOS suite.
Roche Diagnostics CEO Matt Sause said: “Axelios 1 will deliver a disruptive sequencing solution that combines high accuracy with unprecedented speed and scalability.
“These attributes, combined with our high level of cost efficiency, will enable the sequencing community to develop applications that previously were not feasible.
“Additionally, in the future, Axelios 1 has the same potential to enable the next generation of clinical applications and unlock new frontiers in personalised healthcare.”
Axelios 1 utilises SBX chemistry to create Xpandomers, surrogate polymers from deoxyribonucleic acid or ribonucleic acid that are then measured by a sequencing instrument equipped with a reusable complementary metal-oxide-semiconductor sensor containing millions of nanopores.
Roche stated that this method allows the platform to handle both small and large projects and to produce same-day whole genome results without changing systems.
The platform is provided with an open-source analysis suite and is designed for compatibility with other life sciences tools. Roche clarified that Axelios 1 is not for diagnostic procedures.
Earlier this month, Roche announced the rapid development of a research-use-only molecular polymerase chain reaction test to detect the rare Ebola Bundibugyo virus.
